# Phrenix Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/phrenix-therapeutics

- Industry: Biotechnology
- Headquarters: Australia
- Website: www.phrenixtx.com/
- Latest round: Seed (Feb 3, 2025)
- Investors on record: 2

## About

Founded in 2022, Phrenix Therapeutics specializes in creating innovative therapies that address severe psychiatric and neurological conditions. The firm is based in Australia and has completed two notable deals since its inception. The company was co-founded by Chris Langmead (CEO), Greg Stewart, and Jess Nithianantharajah. In February 2025, Phrenix Therapeutics raised an amount of Seed funding from investors Curie.Bio and Brandon Capital Partners.

Phrenix Therapeutics specializes in the development of G protein-coupled receptor (GPCR) targeted therapeutics aimed at addressing cognitive, psychiatric, and neurological disorders. By employing structure-guided design and disease-relevant analytical pharmacology, the company’s core offerings are therapeutics that seek to improve clinical outcomes for patients suffering from these conditions. Utilizing innovative rodent touchscreen-based technologies, Phrenix evaluates therapeutic targets and assesses the efficacy of pro-cognitive compounds, ensuring that their research reflects real-world clinical scenarios rather than historical methodologies. The end users of these products include individuals affected by various psychiatric and neurological disorders, as well as healthcare providers looking for advanced treatment options. Phrenix Therapeutics primarily aims to serve markets where there is a significant demand for improved psychiatric and neurological treatment solutions, including North America, Europe, and Australia. 

Phrenix Therapeutics has successfully closed a Seed funding round to advance its drug discovery pipeline, indicating strong initial financial backing from leading venture capital firms. Revenue generation is structured around strategic partnerships and collaborations with research institutions and healthcare providers, focusing on delivering advanced therapeutic solutions. The company engages in B2B transactions, collaborating directly with healthcare professionals and institutions interested in its GPCR-targeted therapeutics. 

In February 2025, Phrenix Therapeutics raised an undisclosed amount of Seed funding from new investors Curie.Bio and Brandon Capital Partners. The company will use the funding to accelerate its development of treatments for neurological illnesses. Future growth plans include the launch of new GPCR-targeted therapeutics aimed at enhancing patient outcomes in cognitive health, although specific product release dates have not been disclosed. Phrenix also aims to expand into new geographic regions, specifically targeting North America and Europe by 2026.

## Funding rounds

- Seed, Feb 3, 2025 — Brandon Capital Partners, Curie.Bio

## Investors

- Brandon Capital Partners (https://capitalatlas.ai/funds/brandon-capital-partners) — Seed
- Curie.Bio (https://capitalatlas.ai/funds/curie-bio) — Seed